- Home
- MNPR vs EVTL Comparison
MNPR vs EVTL Comparison
Compare MNPR & EVTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- EVTL
- Stock Information
- Founded
- MNPR 2014
- EVTL 2016
- Country
- MNPR United States
- EVTL United Kingdom
- Employees
- MNPR 12
- EVTL N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- EVTL Aerospace
- Sector
- MNPR Health Care
- EVTL Industrials
- Exchange
- MNPR Nasdaq
- EVTL Nasdaq
- Market Cap
- MNPR 292.9M
- EVTL 91.5M
- IPO Year
- MNPR 2019
- EVTL N/A
- Fundamental
- Price
- MNPR $48.50
- EVTL $4.80
- Analyst Decision
- MNPR Strong Buy
- EVTL Buy
- Analyst Count
- MNPR 4
- EVTL 4
- Target Price
- MNPR $43.00
- EVTL $9.50
- AVG Volume (30 Days)
- MNPR 67.7K
- EVTL 704.9K
- Earning Date
- MNPR 03-27-2025
- EVTL 03-13-2025
- Dividend Yield
- MNPR N/A
- EVTL N/A
- EPS Growth
- MNPR N/A
- EVTL N/A
- EPS
- MNPR N/A
- EVTL N/A
- Revenue
- MNPR N/A
- EVTL N/A
- Revenue This Year
- MNPR N/A
- EVTL N/A
- Revenue Next Year
- MNPR N/A
- EVTL N/A
- P/E Ratio
- MNPR N/A
- EVTL N/A
- Revenue Growth
- MNPR N/A
- EVTL N/A
- 52 Week Low
- MNPR $1.55
- EVTL $3.55
- 52 Week High
- MNPR $49.98
- EVTL $15.99
- Technical
- Relative Strength Index (RSI)
- MNPR 66.31
- EVTL 36.80
- Support Level
- MNPR $34.41
- EVTL $4.59
- Resistance Level
- MNPR $44.86
- EVTL $5.33
- Average True Range (ATR)
- MNPR 5.69
- EVTL 0.86
- MACD
- MNPR 1.13
- EVTL -0.45
- Stochastic Oscillator
- MNPR 91.91
- EVTL 6.77
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About EVTL Vertical Aerospace Ltd.
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a global aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero operating emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.